 Mirum Pharmaceuticals Inc NASDAQ: MIRM and Takeda Pharmaceutical Company Limited NYSE: TAK have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome ALGS, progressive familial intrahepatic cholestasis PFIC, and biliary atresia BA. Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. 